Daniel Brune, MD
Family Medicine · Creve Coeur, ILNPI 1982896551
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $33,558 of the $53,255 with a category attached, or 63.0%. It is spread thinly across 56 manufacturers, the largest accounting for just 18.2%. Reporting peaked in 2023 at $13,761 and has fallen 65.0% since, to $4,813 in 2025. Among family medicine clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,754 payments — averaging $30.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$10K
- Idorsia Pharmaceuticals US Inc$8K
- Boehringer Ingelheim$4K
- Modernatx, Inc.$3K
- AstraZeneca$3K
- Abbott$2K
- plus $23K from 50 others
Across 3,048 payments — averaging $4923.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi Pasteur Inc.$5.4M
- Modernatx, Inc.$3.5M
- Janssen Research & Development, LLC$2.3M
- Pfizer$1.5M
- Merck$734K
- Takeda Pharmaceuticals U.S.A., Inc.$495K
- plus $1.2M from 6 others
What the payments were for
- Consulting fees$2,4905%
- Speaking & faculty fees$14,41227%
- Travel & lodging$2,6485%
- Food & beverage$33,55863%
- Education$1270%
- Gifts$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Dayvigo$9,205
- QUVIVIQ$7,567
- FARXIGA$581
- ZENPEP$387
- FASENRA$314
- Vascepa$232
- SOLIQUA 100/33$226
- JARDIANCE$214
- Ozempic$214
- SYMBICORT$202
- BREZTRI AEROSPHERE$202
- XCOPRI$150
- BREZTRI$137
- GENERAL PAIN MANAGEMENT$125
- FreeStyle Libre Pro$125
- ENTRESTO$125
- VRAYLAR$125
- QULIPTA$125
- Tymlos$117
- FREESTYLE LIBRE 3$116
How this compares
$53,255 in reported general payments places this provider in the 95th percentile of 4,116 family medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 24 | $141,586 |
| JardianceEmpagliflozin | 77 | $66,025 |
| OzempicSemaglutide | 42 | $55,975 |
| EliquisApixaban | 51 | $45,746 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 35 | $38,167 |
| XareltoRivaroxaban | 27 | $29,812 |
| FarxigaDapagliflozin Propanediol | 27 | $25,460 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $16,677 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 14 | $13,765 |
| Repatha SureclickEvolocumab | 22 | $13,506 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 436 | $12,967 |
| EntrestoSacubitril/Valsartan | 11 | $12,217 |
| MounjaroTirzepatide | 11 | $11,600 |
| TrulicityDulaglutide | 11 | $10,682 |
| JanuviaSitagliptin Phosphate | 14 | $10,486 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $1,017 | $141,58624 claims |
| Boehringer IngelheimJardiance | $3,712 | $66,02577 claims |
| Novo NordiskOzempic | $1,349 | $55,97542 claims |
| PfizerEliquis | $641 | $45,74651 claims |
| GSKTrelegy Ellipta | $1,796 | $38,16735 claims |
| Johnson & JohnsonXarelto | $132 | $29,81227 claims |
| AstraZenecaFarxiga, Symbicort | $3,105 | $28,45441 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,894 | $22,28222 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $978 | $13,76514 claims |
| NovartisEntresto | $1,509 | $12,21711 claims |
| MerckJanuvia | $459 | $10,48614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,116 family medicine providers in Illinois.
Other family medicine in Creve Coeur
- Frank PhillipsChicago$1.6M
- Peter TothSterling$1.4M
- Bradley TorphyChicago$1.3M
- Jeffrey RoyceRockford$890K
- Anthony AuriemmaWestmont$788K
- Manfred ManGurnee$764K
- Barbara BellarOakbrook Terrace$599K
- Bernie RancheroAltamont$533K
- Sandy GibsonChicago$309K
- Mandy GittlerChicago$204K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.